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Des-Acyl Ghrelin Fragments and Analogues Promote Survival of Pancreatic β-Cells and 
Human Pancreatic Islets and Prevent Diabetes in Streptozotocin-Treated Rats 
 
Abstract 
Des-acyl ghrelin, although devoid of binding to ghrelin receptor (GRLN), exerts many biological 
effects, including regulation of glucose and lipid metabolism. Indeed, des-acyl ghrelin promotes 
pancreatic β-cell and human islet cell survival and prevents diabetes in streptozotocin (STZ) treated 
rats. We investigated whether des-acyl ghrelin fragments excluding serine
3
, which is essential for 
binding to GRLN, would display similar actions. Among the different compounds tested, des-acyl 
ghrelin(6–13) and des-acyl ghrelin(6–13) with alanine substitutions or cyclization, but not with d-amino 
acid substitutions, showed the best survival effect, similar to des-acyl ghrelin. Des-acyl ghrelin(6–13) 
even prevented diabetes in STZ-treated rats and protected human circulating angiogenic cells from 
oxidative stress and senescence, similar to des-acyl ghrelin. These results suggest that not only full-
length des-acyl ghrelin but also short des-acyl ghrelin fragments have clear beneficial effects on 
several tissues in vitro and in vivo. 
Ghrelin is a 28 amino acid peptide mainly produced by the stomach but also in other tissues such as 
the gastrointestinal tract and the pancreas.(1, 2) Ghrelin potently stimulates growth hormone (GH) 
release from the pituitary and exerts orexigenic activities at the central level.(3) These 
neuroendocrine actions require acylation on the third serine residue by ghrelin O-acyl transferase 
(GOAT), and ghrelin acylaton is essential for binding to its receptor, the GH secretagogue receptor 
type 1a (GHS-R1a), lately designated GRLN.(1, 4-8) 
Besides the hypothalamus–pituitary and other central areas, GRLN is distributed in peripheral 
tissues, including the endocrine pancreas and adipose tissue.(2, 3) Consistently, ghrelin elicits many 
peripheral actions, including regulation of pancreatic β-cell function and influence on glucose and 
lipid metabolism.(9-12) Mice deleted for both ghrelin and GRLN genes show improved glucose 
tolerance and insulin secretion and sensitivity under high-fat diet treatment. In obese, leptin-
deficient (ob/ob) mice, ablation of ghrelin was found to increase insulin release and to reduce 
hyperglycemia, suggesting negative effects of ghrelin on insulin secretion and glucose 
metabolism.(13, 14) Notably, ghrelin infusion in humans induces acute insulin resistance and 
lipolysis, and ghrelin levels are strongly increased in insulin-resistant obese individuals, suggesting 
that ghrelin may contribute to insulin resistance in obesity.(15, 16) 
At variance with ghrelin, des-acyl ghrelin is devoid of endocrine activities and GRLN binding. 
However, des-acyl ghrelin is the most abundant circulating form of ghrelin, exerting a variety of 
effects, including positive actions on glucose and lipid metabolism.(3, 9, 17) Indeed, des-acyl 
ghrelin has been shown to modulate the expression of metabolic genes in GRLN-deleted mice 
tissues, to inhibit lipolysis in adipocytes, and to counteract the ghrelin diabetogenic actions in 
animals and humans.(18-20) 
On the basis of des-acyl ghrelin inabilit to bind GRLN, the existence of a different and yet unknown 
receptor involved in the effects of the peptide has been proposed. Indeed, common binding sites for 
both ghrelin and des-acyl ghrelin have been shown in pancreatic β-cells and in a variety of cell 
types, where both ghrelin and des-acyl ghrelin exert similar effects.(20-22) 
Pancreatic β-cell survival is of major importance for maintaining normal glucose metabolism, and 
β-cell apoptosis is a critical event in both type 1 and type 2 diabetes.(23, 24) We have recently 
demonstrated that des-acyl ghrelin, like ghrelin, counteracts serum starvation-induced and cytokine-
induced β-cell death and apoptosis.(22) In addition, des-acyl ghrelin, like ghrelin and obestatin, the 
other ghrelin gene-derived peptide, was found to prevent diabetes at adult age in streptozotocin 
(STZ) treated neonatal rats by reducing blood glucose, and increasing β-cell mass and insulin 
secretion.(25) These findings indicated that des-acyl ghrelin and ghrelin exert similar effects on β-
cell survival. However, on the basis of its greater positive effects on insulin sensitivity and glucose 
homeostasis, des-acyl ghrelin is a more appealing candidate for the treatment of metabolic 
dysfunctions such as insulin resistance and type 2 diabetes. 
This study aimed at verifying whether des-acyl ghrelin fragments would mimic the actions of full 
length des-acyl ghrelin(1–28) on survival of β-cells and human pancreatic islets. These fragments 
either included or excluded serine3, the site for ghrelin acylation that is essential for GRLN 
binding.(3) 
Results 
 
Des-Acyl Ghrelin(1–14) (Compound 3) and Des-Acyl Ghrelin(1–18) (Compound 2), but Not Des-Acyl 
Ghrelin(1–5) (Compound 4) and Des-Acyl Ghrelin(17–28) (Compound 5), Promote HIT-T15 β-Cell 
Survival  
Full length des-acyl ghrelin(1–28) (compound 1) has been previously shown to protect pancreatic β-
cells and human pancreatic islets from cell death induced by either serum starvation or 
inflammatory cytokines, whose synergism is involved in β-cell death in both type 1 and type 2 
diabetes.(22, 26) Here, we investigated the survival effects of des-acyl ghrelin fragments in HIT-
T15 β-cells and human pancreatic islets, under both serum starvation and interferon-γ (IFN-
γ)/tumor necrosis factor α (TNF-α)/interleukin-1β (IL-1β) synergism. We initially examined the 
survival effects of fragments including the N-terminal region of des-acyl ghrelin (15–19 amino acid 
length), as well as its N-terminal and C-terminal regions (5–12 amino acid length). 
Compound 1 and its fragments, compounds 2–5 (Table 1 and S1) were tested at increasing 
concentrations ranging from 1 to 100 nM. Compounds 2 and 3 displayed protective effects against 
both serum starvation- and cytokine-induced cell death at all the concentrations tested, similar to 
compound 1 (Figure 1A and C). Conversely, compounds 4 and 5 were inactive (Figure 1B and D). 
 
Figure 1. Survival effect of compounds 1–5 in HIT-T15 β-cells and human 
pancreatic islets. HIT-T15 β-cells (A–D) and human pancreatic islets (E–H) were 
cultured in the presence of serum(s) or serum starved for 24 h, then incubated in 
serum-free medium (SF) for a further 24 h with the fragments, at the 
concentrations indicated, either alone or in the presence of cytokines (100 ng/mL 
IFN-γ, 200 ng/mL TNF-α, and 10 ng/mL IL-1β). Cell survival was assessed by 
MTT. Results are expressed as percent of control (c, serum-free medium for parts 
A, B, E, and F; c, cytokines for parts C, D, G, and H) and are the mean ± SE of at 
least three independent experiments, each performed in quadruplicate (( ) P < 
0.05, ( ) P < 0.01 vs c; ns, not significant). 
Table 1. List of Des-Acyl Ghrelin Fragments 
compd peptide sequence 
1 des-acyl ghrelin(1–28) GSSFLSPEHQRVQQRKESKKPPAKLQPR-COOH 
2 des-acyl ghrelin(1–18) GSSFLSPEHQRVQQRKES-NH2 
3 des-acyl ghrelin(1–14) GSSFLSPEHQRVQQ-NH2 
4 des-acyl ghrelin(1–5) GSSFL-NH2 
compd peptide sequence 
5 des-acyl ghrelin(17–28) ESKKPPAKLQPR-COOH 
6 des-acyl ghrelin(6–13) SPEHQRVQ-NH2 
7 des-acyl ghrelin(8–13) EHQRVQ-NH2 
8 des-acyl ghrelin(8–12) EHQRV-NH2 
9 des-acyl ghrelin(8–11) EHQR-NH2 
10 des-acyl ghrelin(9–12) HQRV-NH2 
11 des-acyl ghrelin(9–11) HQR-NH2 
12 retro-des-acyl ghrelin(1–14) QQVRQHEPSLFSSG-COOH 
Compounds 2 and 3, but Not Compounds 4 and 5, Promote Human Pancreatic Islet Cell Survival  
Compound 1 increased human islet cell survival at all the concentrations tested and in both 
conditions except for 1 nM in serum starved cells. Compound 3 was effective in serum deprived 
medium at both 10 and 100 nM, whereas under cytokine treatment the survival effect was observed 
only at 100 nM (Figure 1E and G). Compound 2 increased islet cell survival at 1 and 10 nM, but not 
at 100 nM, in both experimental conditions (Figure 1E and G). Compounds 4 and 5 were inactive at 
all the concentrations tested (Figure 1F and H). 
These results indicate that compounds 2 and 3 increase islet cell survival in serum deprived 
medium, similar to compound 1. Their survival action is instead reduced in the presence of 
cytokines, where des-acyl ghrelin-induced protection is maintained. 
Effect of Des-Acyl Ghrelin(6–13) (Compound 6), Des-Acyl Ghrelin(8–13) (Compound 7), Des-Acyl 
Ghrelin(8–12) (Compound 8), Des-Acyl Ghrelin(8–11) (Compound 9), Des-Acyl Ghrelin(9–12) 
(Compound 10), and Des-Acyl Ghrelin(9–11) (Compound 11) on HIT-T15 β-Cell Survival  
We next determined whether small fragments of eight to three amino acids, corresponding to the 
central part of compound 2 (Tables 1 and S1), would display biological effects. 
The survival effect of compounds 6–11, compared to that of compound 1, was assessed in cytokine-
treated HIT-T15 β-cells. As expected, cytokine synergism strongly reduced cell survival with 
respect to normal culture conditions (serum containing medium) (Figure 2A). Compound 6, at all 
the concentrations tested (1–100 nM) and particularly at 100 nM, potently inhibited cytokine-
induced cell death by increasing cell survival to values similar to or even greater than those of 
serum. This effect was comparable to that of compound 1 (Figure 2A). 
 
Figure 2. Survival and antiapoptotic effects of small des-acyl ghrelin fragments in 
HIT-T15 β-cells and human pancreatic islets. HIT-T15 β-cells were starved for 24 
h and incubated for further 24 h in the presence or absence of cytokines (CK) (100 
ng/mL IFN-γ, 200 ng/mL TNF-α, and 10 ng/mL IL-1β) either alone or with the 
indicated compounds. Human islet cells were incubated for 72 h in the presence of 
serum or in serum-free medium either alone or with IFN-γ/TNF-α/IL-1β (5 ng/mL 
each) and the indicated peptides. (A) HIT-T15 β-cell survival assessed by MTT. 
The peptides were used at the concentrations indicated. Compound 12 was used as 
control peptide. Results are the mean ± SE of at least three independent 
experiments, each performed in quadruplicate (( ) P < 0.05, ( ) P < 0.01 vs 
control (ns, not significant). (B) Hoechst 33258 nuclear staining (magnification 
×200) of HIT-T15 β-cells treated with cytokines either alone or with the indicated 
fragments (100 nM). (C–E) HIT-T15 β-cell apoptosis assessed by counting 
condensed/fragmented Hoechst-stained nuclei. Compounds 1 and 3 were used at 
100 nM (s, serum; SF, serum-free medium; CK, cytokines). Values are expressed 
as percent of apoptotic cells and are the mean ± SE of duplicate determinations 
(500 cells each) (n = 3) (( ) P < 0.05, ( ) P < 0.01 vs CK; ns, not significant). 
(F, G) Cell survival assessed by MTT in human pancreatic islets. Compound 12 
(100 nM) was used as control peptide. Results are the mean ± SE of at least three 
independent experiments, each performed in quadruplicate (( ) P < 0.05, ( ) P 
< 0.01 vs control; ns, not significant). 
Compound 7, although less than compound 6, increased cell survival at all the concentrations 
examined. Compound 8 and to a similar extent compound 10 displayed significant, although 
reduced, survival action at 10 and 100 nM only. Compounds 9 and 11 showed reduced or no effect. 
Retro des-acyl grelin(1–14) (compound 12) used as negative control in these experiments was 
inactive. 
These results suggest that among the different des-acyl ghrelin fragments examined, compound 6 is 
the most potent in counteracting cytokine-induced β-cell death. 
Compounds 6–8 Inhibit Cytokine-Induced Apoptosis in HIT-T15 β-Cells  
The antiapoptotic effect of compounds 6–8 was next investigated in cytokine-treated HIT-T15 β-
cells. As previously reported,(22) apoptosis, assessed by Hoechst staining of apoptotic nuclei, 
increased under cytokine treatment with respect to serum starvation alone, the cells appearing 
smaller, scattered, and with fragmented and condensed nuclei (Figure 2B). Compound 6 strongly 
increased the amount of cells, preserved their shape, and increased small islet formation with 
respect to cytokine treatment alone (Figure 2B). Moreover, it reduced cytokine-induced apoptosis at 
1 and 10 nM and, particularly, at 100 nM, where the antiapoptotic effect was even stronger than that 
displayed by compound 1 (Figure 2C). 
Compound 7, although less than compound 6, reduced apoptosis at 10 and 100 nM (Figure 2B and 
D), whereas compound 8 was effective only at 100 nM (Figure 2B and E). Compound 12, used as 
negative control, was inactive (Figure 2C–E). 
These results indicate that, as for cell survival, compound 6 is the most potent antiapoptotic 
fragment in cytokine-treated β-cells. 
Compound 6 Promotes Human Pancreatic Islet Cell Survival  
In human pancreatic islets, the survival effect of compound 6 was investigated in both serum 
starved conditions and cytokine synergism. Exendin-4 (Ex-4), an analogue of glucagon-like 
peptide-1 (GLP-1), which is known to exert survival and antiapoptotic effects in β-cells and human 
islets,(27) was used as positive control. In both conditions compound 6 increased islet cell survival 
at 10 and 100 nM with respect to control. These effects were similar to those of compound 1, 
although reduced compared to Ex-4. Compound 12, used as negative control, was inactive (Figure 
2F and G). 
Effect of Des-Acyl Ghrelin(6–13) with Either Alanine- or d-Amino Acid Substitutions on HIT-T15 β-
Cell Survival  
Alanine (Ala) substitutions have been used to determine the contribution of each amino acid to the 
biological activity of peptide.(28) Moreover, D-scans, substitution of l- by d-amino acids, were 
principally used to probe conformational effects when conducted as part of a structure–activity 
relationship (SAR). Indeed, amino acid configuration scan as a means of revealing the 
stereochemical SAR is an important facet in developing peptides.(28, 29) 
The contribution of the amino acid side chains to the survival action of compound 6 was evaluated 
by systematic alanine replacement of each residue of the peptide sequence (compounds 13–20, 
Tables 2 and S1). As expected, compound 6 increased β-cell survival in serum-free medium (Figure 
3A). All the peptides with Ala replacement, except [Ala
10
]des-acyl ghrelin(6–13) (compound 17) and 
[Ala
11
]des-acyl ghrelin(6–13) (compound 18), showed survival action comparable to that of 
compound 6 at both the concentrations tested (1 and 100 nM) (Figure 3A). Similar effects were 
observed under cytokine treatment, where all compounds with Ala substitutions, except compounds 
17 and 18, increased cell viability (Figure 3B). These results suggest that Ala replacement at 
positions 6–9 (compounds 13–16) and 12 and 13 (compounds 19 and 20) does not substantially 
affect the activity of des-acyl ghrelin(6–13), whereas Ala substitution at position 10 (Gln
10
) or 11 
(Arg
11
) (compounds 17 and 18) results in a complete loss of activity. 
 
Figure 3. Effect of des-acyl ghrelin(6–13) with Ala or d-amino acid substitutions at 
positions 6–13 on HIT-T15 β-cell survival. The indicated peptides were tested by 
MTT at either 1 or 100 nM in both serum deprived medium and in the presence of 
cytokines. Cells were cultured in serum-free medium for 24 h and for further 24 h 
in serum starved medium alone or with cytokines (100 ng/mL IFN-γ, 200 ng/mL 
TNF-α, and 10 ng/mL IL-1β): (A, B) des-acyl ghrelin(6–13) with Ala substitutions; 
(C, D) des-acyl ghrelin(6–13) with d-amino acid substitutions; (E, F) enantiomer of 
des-acyl ghrelin(6–13) (rev, reverse fragment). Results are expressed as percent of 
the control (serum starvation for parts A, C, and E; cytokines for parts B, D, and 
F) and are the mean ± SE of three independent experiments, each performed in 
quadruplicate (( ) P < 0.05, ( ) P < 0.01). 
Table 2. Des-Acyl Ghrelin(6-13) Derivatives and Analogues 
chemical modification compd peptide sequence 
alanine substitution 13 [Ala
6
] des-acyl ghrelin(6–13) APEHQRVQ-NH2 
  14 [Ala
7
] des-acyl ghrelin(6–13) SAEHQRVQ-NH2 
  15 [Ala
8
]des-acyl ghrelin(6–13) SPAHQRVQ-NH2 
  16 [Ala
9
]des-acyl ghrelin(6–13) SPEAQRVQ-NH2 
  17 [Ala
10
]des-acyl ghrelin(6–13) SPEHARVQ-NH2 
  18 [Ala
11
]des-acyl ghrelin(6–13) SPEHQAVQ-NH2 
  19 [Ala
12
]des-acyl ghrelin(6–13) SPEHQRAQ-NH2 
  20 [Ala
13
]des-acyl ghrelin(6–13) SPEHQRVA-NH2 
d-amino acid substitution 21 [d-Ser
6
]des-acyl ghrelin(6–13) sPEHQRVQ-NH2 
  22 [d-Pro
7
]des-acyl ghrelin(6–13) SpEHQRVQ-NH2 
  23 [d-Glu
8
]des-acyl ghrelin(6–13) SPeHQRVQ-NH2 
  24 [d-His
9
]des-acyl ghrelin(6–13) SPEhQRVQ-NH2 
  25 [d-Gln
10
]des-acyl ghrelin(6–13) SPEHqRVQ-NH2 
  26 [d-Arg
11
]des-acyl ghrelin(6–13) SPEHQrVQ-NH2 
  27 [d-Val
12
]des-acyl ghrelin(6–13) SPEHQRvQ-NH2 
  28 [d-Gln
13
]des-acyl ghrelin(6–13) SPEHQRVq-NH2 
cyclization 29 cyclo(des-acyl ghrelin(6–13)) c(SPEHQRVQ) 
full length d-amino acid substitutions 30 d-des-acyl ghrelin(6–13) spehqrvq-NH2 
  31 retro-d-des-acyl ghrelin(6–13) qvrqheps-NH2 
Des-acyl ghrelin(6–13) fragments with d-amino acid substitution at different amino acid positions (6–
13) were also tested on HIT-T15 β-cell survival (compounds 21–28, Tables 2 and S1). d-Amino 
replacement at positions 6–13 (Tables 2 and S1) led to analogues totally devoid of survival effect in 
both experimental conditions (Figure 3C and D). Similar effects were observed with enantiomer of 
des-acyl ghrelin(6–13) (d-des-acyl ghrelin(6–13), compound 30) and the reverse enantiomer of des-acyl 
ghrelin(6–13) (retro d-des-acyl ghrelin(6–13), compound 31) (Tables 2 and S1 and Figure 3E and 
F). 
These findings suggest that, at variance with Ala substitutions, d-amino acid replacements are 
detrimental for the biological activity of compound 6. Moreover, they indicate that there is a 
pronounced stereochemical SAR in that peptide, based on the d-amino acid scan results. 
Effect of Des-Acyl Ghrelin(6–13) with Cyclization on HIT-T15 β-Cell Survival  
Cyclization has been previously shown to increase the stability of small peptides;(30, 31) therefore, 
we assessed the survival effect of cyclo-des-acyl ghrelin(6–13) (compound 29) (Tables 2 and S1) 
(head-to-tail cyclization) in HIT-T15 β-cells cultured in both serum starved and cytokine synergism, 
compared to that of compounds 1 and 6. 
Compound 29 dose-dependently increased cell survival in both experimental conditions and at all 
concentrations tested (1–100 nM), similar to compounds 1 and 6 (Figure 4). These results suggest 
that the in vitro survival action of des-acyl ghrelin(6–13) is maintained after cyclization. No effect 
was observed with compound 12 (100 nM) at any condition tested. 
 
Figure 4. Survival effects of des-acyl ghrelin(6–13) with cyclization. The peptides 
were tested by MTT at the indicated concentrations in HIT-T15 β-cells in serum-
free medium for 24 h (A) or for further 24 h in serum-free medium (SF) with 
cytokines (100 ng/mL IFN-γ, 200 ng/mL TNF-α, and 10 ng/mL IL-1β) (B). 
Results are expressed as percent of the control (c, serum starvation and cytokines 
for A and B, respectively) (n = 3; , P < 0.05; , P < 0.01). 
Effect of Compound 6 in Streptozotocin (STZ) Induced Diabetes  
Both ghrelin and des-acyl ghrelin have been shown to prevent diabetes in STZ-treated rats.(25, 32) 
Therefore, we examined the long-term effects of early treatment with compound 6, compared to 
those of compound 1, in neonatal rats treated with STZ at day 1 of birth. Compound 6 was tested at 
concentrations that were either equal to or higher than that of compound 1 (30 and 100 nmol/kg, 
respectively). At day 9 after STZ injection, the animal survival rate, which was decreased by STZ 
with respect to the control group ( 52%), was strongly increased by compound 1 ( 72%), as well 
as by both concentrations of compound 6 ( 71% and 89% for 30 and 100 nmol/kg, respectively) 
(Figure 5A). At day 70, plasma glucose was markedly increased in the STZ group. Compound 1, as 
expected, reduced STZ-induced glucose increase, and compound 6 showed a similar effect, 
although the higher concentration tested was found to be less effective (Figure 5B). Compound 6, 
like compound 1, also counteracted STZ-induced reduction of plasma and pancreatic insulin (Figure 
5C and D). In untreated animals receiving saline, the peptides alone had no effect on glucose and 
insulin levels (data not shown). 
 Figure 5. Effects of compound 6 in rats treated with STZ (100 mg/kg body 
weight) with or without 30 nmol/kg compound 1, compound 6 at 30 nmol/kg, or 
compound 6 at 100 nmol/kg. (A) Animal survival at day 9. Data are expressed as 
percent of control (animals injected with a single dose of citrate buffer). Plasma 
glucose (B), plasma insulin (C), and pancreatic insulin (D) levels in 70-day-old 
rats. Control, rats treated with citrate buffer. Results are expressed as the means ± 
SE: control group (n = 11); STZ group (n = 11); STZ + compound 1 group (n = 
16); STZ + compound 6, 30 nmol/kg group (n = 21); STZ + compound 6, 100 
nmol/kg group (n = 15). , P < 0.01. 
These results suggest that compound 6 counteracts the diabetogenic effects of STZ in rats as 
potently as compound 1. 
Compounds 6 and 29 Protect Human Circulating Endothelial Progenitor Cells (EPCs) from 
Oxidative Stress and Prevent EPC Senescence  
Several lines of evidence indicate that overproduction of reactive oxygen species (ROS) contributes 
to the impaired EPC bioavailability in diabetes.(33, 34) We have previously reported that des-acyl 
ghrelin protects human EPC from ROS generation;(17) therefore, the protective effect of 
compounds 6 and 29 on hydrogen peroxide (H2O2) treated cells was also evaluated. Figure 6A 
shows that, as for compound 1, compounds 6 and 29 drastically reduced ROS production in 
response to H2O2. Consistent with our previous findings,(17) treatment with either compound 6 or 
29 also prevented Rac1 activation, which has been shown to be required for Nox2-mediated ROS 
production (data not shown).(35) 
 
Figure 6. Effects of compounds 6 and 29 on ROS production and senescence in 
EPCs. (A) ROS production assessed by flow cytometry (DCF-DA assay) in cells 
treated with H2O2 for 2 h: left panels, fragments alone; right panels, fragments 
with H2O2. (B) Cell senescence evaluated by measuring the acidic β-gal (SA-β-
gal) activity 24 h after addition of the indicated stimuli. Results are expressed as 
the percentage of SA-β-gal-positive cells (( ) P < 0.05, H2O2 vs untreated; (#) P < 
0.05 vs H2O2 control. Results are the mean ± SE from three independent 
investigators. 
 
Figure 7. Model of the predicted structure of compounds 6 (A) and 29 (B). 
The above results prompted us to evaluate whether the increased ROS production, generally 
considered as an upstream signal, translates into an accelerated onset of senescence and whether 
compounds 6 and 29 could rescue this effect. As for compound 1, compounds 6 and 29 reduced the 
number of senescence-associated β-galactosidase (SA-β-gal) positive EPCs in response to H2O2 
(Figure 6B). 
Peptide Molecular Modeling  
Ghrelin and des-acyl ghrelin were first considered to not possess a well-defined secondary and 
tertiary structure in solution as defined by circular dichroism (CD) and nuclear magnetic resonance 
spectroscopy.(36) However, more recent studies performed using molecular dynamic 
simulation(37) and in silico 3D model or CD spectroscopy(38) showed a clear formation of a short 
α-helix from Pro7 to Glu13 and from Pro7 to Ser18, respectively. Currently, the molecular structure of 
compound 6 has not been analyzed. A blast search on Protein Data Bank (PDB) sequences was 
performed on compound 6. No similar structural motif was found. Basic computer molecular 
modeling of compounds 6 and 29 was performed using Insight II, a comprehensive graphic 
molecular modeling program, minimized by the use of conjugate gradient after molecular dynamics. 
The model of compound 6 (Figure 7A) suggests that this compound has an α-helix structure as 
previously described for the full length des-acyl ghrelin peptide using molecular dynamic 
simulation(37) and in silico 3D model and CD spectroscopy.(38) The model of compound 29 
(Figure 7B) seems to have a more constrained structure with a turn at Arg
11
-Val
12
. This structure 
could potentially be stabilized by interactions between the carbonyl group of Gln
10
 and the amine 
group of Val
12
, Gln
13
, and Ser
6
. 
Discussion 
 
This study shows that des-acyl ghrelin fragments, particularly compound 6 and its analogues, exert 
survival effects in pancreatic β-cells and human pancreatic islets, which are comparable to those of 
their parent molecule. Compound 6 also inhibits STZ-induced diabetes in rats and reduces oxidative 
stress and senescence in human circulating angiogenic cells. 
We focused on des-acyl ghrelin and not on ghrelin because of the previously reported positive 
effects of des-acyl ghrelin on glucose and lipid metabolism, which are opposed to the insulinostatic 
actions of ghrelin.(12-15, 15-17, 23) Des-acyl ghrelin fragments were tested in HIT-T15 β-cells and 
human pancreatic islets, which were previously used to demonstrate the survival and antiapoptotic 
effects of all the ghrelin gene products (ghrelin, des-acyl ghrelin, and obestatin).(22, 39) β-Cells and 
human islets were cultured in either serum deprived medium or in the presence of cytokines whose 
synergism causes β-cell destruction in both type 1 and type 2 diabetes.(23, 24) 
Among the different fragments, those including amino acids at positions 1–14 and 1–18 increased 
survival in both HIT-T15 β-cells and human pancreatic islets, under either serum starvation or 
cytokine synergism. Conversely, those comprising amino acids 1–5 and 17–28 (N-terminal and C-
terminal, respectively) were totally devoid of activity. These results initially suggested that the 
biologically active domain of des-acyl ghrelin is located in its N-terminal part of the peptide, likely 
including amino acids 1–18. 
When testing a number of small fragments, comprising eight to three amino acids, we observed that 
the most potent survival effect against cytokine-induced β-cell destruction was harbored by the 
central region of des-acyl ghrelin, particularly that including amino acids at positions 6–13. Indeed, 
compound 6, more than any other, not only increased cell survival but also potently inhibited 
cytokine-induced apoptosis in HIT-T15 β-cells. In addition, compound 6 even increased survival in 
human pancreatic islets under both serum starvation and cytokine synergism, and this effect 
resembled that of compound 1. 
Interestingly, compound 4, which includes Ser
3
, the site for octanoylation responsible for binding to 
GRLN and for the endocrine activities of ghrelin, was found here to be inactive when not acylated 
with n-octanoic acid. Conversely, compound 6 displayed strong biological activity, comparable to 
that of compound 1. These opposite findings further suggest the existence of different receptors 
involved in the effects of either ghrelin or des-acyl ghrelin/des-acyl ghrelin fragments. Interestingly, 
a recent study from Bednarek et al. confirmed that the n-octanoyl group of ghrelin is one of the 
principal structural features determining its potency for GRLN binding.(40) This paper even 
showed that Ser2 octanoylation is similar to Ser3 in terms of binding to GRLN, suggesting that 
GRLN does not distinguish between Ser(n-octanoyl) in position 2 or 3. 
Naturally occurring cyclic proteins, which have been found in bacteria, plants, and animals, show 
improved activity and exceptional stability; therefore, protein cyclization to improve their in vivo 
half-life is of potential great importance for proteins of therapeutic value.(30, 31) Here, we tested 
the effects of compound 29, which normally occurs in linear form. Interestingly, the in vitro 
survival effect of des-acyl ghrelin(6–13) was fully maintained after cyclization, suggesting the 
possibility of synthesizing cyclic fragments with increased stability and improved pharmacokinetic 
properties for clinical use. However, in the present study, des-acyl ghrelin analogues were often 
observed to be without dose response effect. Whether or not this is due to lack of power of the study 
design (cell-specific response, noise in the experiments) or that another factor causes it is difficult to 
answer. Moreover, the lack of dose-dependent effects is not supportive of a receptor specific to des-
acyl ghrelin or the foregoing fragments thereof. Definitely, there is a need for more in vitro and in 
vivo data that give a broader insight into the mechanisms and the pharmacodynamics of des-acyl 
ghrelin and its potential analogues. 
The biological activity of compound 6 was also assessed in vivo in adult diabetic rats that were 
treated with STZ at neonatal age. We have previously demonstrated the antidiabetogenic actions of 
des-acyl ghrelin in this animal model of type 1 diabetes and suggested that these effects were at 
least partly due to the des-acyl ghrelin survival actions in pancreatic β-cells.(22, 25) Here, the 
effects of compound 6 were tested at concentrations that were either equivalent or higher than that 
of compound 1, which was used as control peptide. The parameters selected comprised plasma 
glucose levels, which were reduced by compound 6 in STZ-treated rats, and plasma and pancreatic 
insulin levels, both increased by compound 6 in the same conditions. These results suggest that 
compound 6, like compound 1, prevents STZ-induced diabetes. Moreover, on the basis of the strong 
survival effects in β-cells, compound 6 likely elicits its antidiabetogenic actions in vivo, at least 
partly by reducing the detrimental effects of STZ on β-cell mass. 
Interestingly, as previously demonstrated for des-acyl ghrelin, compounds 6 and 29 were found here 
to protect EPCs from oxidative stress and senescence, further supporting the hypothesis that the 
des-acyl ghrelin biological activity may reside in its central region, excluding the site for 
octanoylation. 
Likely, the effects observed for both des-acyl ghrelin and active des-acyl ghrelin fragments do not 
involve GRLN. In addition, although specific des-acyl ghrelin binding sites have been previously 
described in different cell types,(20, 21) including β-cells(22) and EPCs,(17) the lack of dose–
response effect often observed in the present study suggests that des-acyl ghrelin and its analogues 
may bind as well to nonspecific receptor(s). 
Interestingly, previous studies have shown that small peptide or non-peptide agonists may act as 
allosteric modulator, binding to a different site of GRLN and either increasing or reducing the 
sensitivity of the receptor for the natural ligand.(41) However, in the present study the cells were 
incubated only with des-acyl ghrelin fragments in the absence of ghrelin, the natural ligand of 
GRLN; therefore, allosterism could not be considered. 
Furthermore, although the effects on survival and apoptosis were found to be statistically 
significant, our data do not automatically imply that des-acyl ghrelin or its analogues will have 
these beneficial effects in a clinical setting. Des-acyl ghrelin analogues for the use in (pre)clinical 
studies are not available to date, and no data exist on prolonged administration of des-acyl ghrelin 
(analogues) in the endocrine pancreas. 
Conclusions 
 
Collectively, the results of this study show that like their parent molecule, des-acyl ghrelin 
fragments, particularly compound 6, increase survival of β-cells and human pancreatic islets, 
prevent STZ-induced diabetes in rats, and reduce oxidative stress and senescence in human EPCs. 
Therefore, these findings suggest that des-acyl ghrelin fragments exhibit the same pharmacological 
profile and therapeutic potential of their parent molecule and may represent promising tools for 
preservation of β-cell mass and impaired vascular growth in metabolic dysfunctions and diabetes. 
Experimental Section 
 
Materials  
Compounds 1–5 and exendin-4 were purchased from Phoenix Pharmaceuticals (Belmont, CA). All 
other fragments were obtained from Tib MolBiol (Genova, Italy). Cell culture reagents were 
purchased from Invitrogen (Milano, Italy). 
Peptide Synthesis, Cleavage, and Purification  
The different peptides were synthesized on solid support on a Symphony peptide synthesizer 
(Protein Technologies Inc., U.S.) at room temperature using the standard manufacturer’s 
procedure.(42) 
Linear Peptides  
C-Terminal free was synthesized (0.8 mmol scale) on a Fmoc-Arg(Pbf)-MPPA(Wang)-MBHA 
resin. All Fmoc-amino acids (8 mmol, 10 equiv) were coupled with PyBOP/HOBt in DMF. 
Reactive side chains were protected as follows: Thr, Ser, and Tyr, tert-butyl (
t
Bu) ether; Lys, tert-
butyloxycarbonyl (Boc) carbamate; Glu, O-tert-butyl (O
t
Bu) ester; Asn, His trityl (Trt), and Arg, 
pentamethyldihydrobenzofuran (Pbf) sulfonylamide. All coupling reactions were monitored by 
Kaiser’s test (or chloranile test for secondary amine). After completion of the chain assembly, the 
peptides were cleaved from the resin and deprotected by adding 40 mL of mixture 
TFA/phenol/H2O/thioanisole/ethanedithiol (82.5:5:5:5:2.5, v/v/v/v/v) agitated at room temperature 
for 3 h. Crude peptides were purified by preparative reverse-phase HPLC (RP-HPLC) on an 
Ultrasep ES column (RP-18, 10 μm, 250 mm × 20 mm) using a linear gradient (0–24% over 30 
min) of acetonitrile/H2O + Et3N + H3PO4 (99.8:0.1:0.1, v/v/v). The peptide was desalted on a C18 
column using 0.1% TFA buffer. 
Synthesis of Compound 29  
Peptide was synthesized (1.5 mmol scale) on Fmoc-Pro-chlorotrityl resin. All Fmoc-amino acids (3 
equiv) were coupled with PyBOP/HOBt/DIEA or DIC/HOBt in DMF. Reactive side chains were 
protected as follows: Ser, tert-butyl (
t
Bu) ether; Glu, O-tert-butyl (O
t
Bu) ester; Gln and His, trityl 
(Trt); and Arg, pentamethyldihydrobenzofuran (Pbf) sulfonylamide. All coupling reactions were 
monitored by Kaiser’s test (or chloranile test for secondary amine). After completion of the chain 
assembly the peptide–resin was treated with HFIP/DCM (15:85, v/v) for 1 h under gentle agitation. 
After filtration of the resin, the filtrate was evaporated under vacuum and precipitated in diisopropyl 
ether. The cyclization was performed in DMF with HATU/NMM. After concentration of DMF, the 
peptide was washed with H2O. Cyclic peptide was deprotected by adding a mixture 
TFA/H2O/ethanedithiol (90:5:5, v/v/v) agitated 3 h at room temperature. Crude peptide was purified 
by three successive preparative reverse-phase purifications using an Ultrasep ES column (RP-18, 10 
μm, 250 mm × 20 mm) and a linear gradient of acetonitrile: first purification with 0.1% TFA buffer, 
second purification with TEA/H3PO4, 0.1%, buffer, third purification with 0.1% TFA buffer. 
Peptide Analysis  
The purified peptides were at least 95% pure as determined by analytical RP-HPLC analysis 
performed on an Ultrasep ES column (RP-18.7 μm, 250 mm × 3.0 mm) using a linear gradient (0–
50% over 20 min) of 0.005% TFA/TFA + acetonitrile + H2O (0.05:80:19.95, v/v/v) (Table S1). The 
peptides were further characterized by MALDI-TOF mass spectrometry on a MALDI 2 DE 
instrument (Shimadzu, Japan). 
Cell Culture  
Hamster HIT-T15 β-cells were obtained and cultured as previously described.(22) 
Human Islet Isolation  
Human islets were obtained from pancreases of multiorgan donors as described.(22, 39) Islet 
preparations with purity of >70%, not suitable for transplantation, were used after approval by the 
local ethical committee. Islets (10 000) were cultured in CMRL (Invitrogen) with 10% FBS. 
Cell Survival Assay  
Cell survival was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
as previously described.(22) Cells were seeded on a 96-well plate at a density of 5 × 103 cells/well 
and 25 islets/well for HIT-T15 cells and human pancreatic islets, respectively. After treatments, 
cells were incubated with 1 mg/mL MTT for 1 h. The medium was aspirated and the formazan 
product solubilized with 100 μL of DMSO. Viability was assessed by spectrophotometer at 570 nm 
absorbance using a 96-well plate reader. 
Hoechst Staining of Apoptotic Cells  
Morphological changes in the nuclear chromatin of apoptotic cells were detected by Hoechst 33258 
staining. HIT-T15 cells, harvested by PBS–EDTA, were pooled with the cells from conditioned 
medium, fixed with 4% formaldehyde in PBS for 15 min at 4 °C, washed, resuspended in 70% 
ethanol, and stored at −20 °C until use. Cells were then washed twice in PBS and stained in 50 μL 
of PBS containing 10 μg/mL Hoechst 33258. Following 15 min of incubation at room temperature, 
a 15 μL aliquot was placed on a glass slide and 500 stained nuclei were double counted under a 
fluorescence microscope (DAPI filter). 
Isolation, Characterization, and Culture of EPCs  
Peripheral blood mononuclear cells were recovered and cultured onto collagen type 1 coated dishes 
for 21 days in EGM-2 medium (Cambrex, Walkersville, MD) as described by Yoder et al.(43) 
Fluorescence activated cell sorter analysis was used to characterize EPC surface markers: CD45, 
CD14, CD34, CD31, Tie-2, KDR, vWF. 
Detection of ROS  
Kinetic analysis of ROS production was performed by using DCF-DA (5(and 6)-carboxy-2′,7′-
dichlorofluorescein diacetate, 0.5 μM final concentration) (Molecular Probe, Invitrogen) assay. The 
majority of experiments using the DCF-DA assay were performed after 2 h of the indicated 
treatments, as previously described.(17) H2O2 (150 μM) was used as positive control. 
EPC Senescence Assay  
Senescence was evaluated by measuring the acidic β-gal activity, as described by Togliatto et 
al.(17) on EPCs treated with or without compound 1 (1 μM), compound 6, or compound 29 (10 
μM). Briefly, EPCs were washed in phosphate-buffered saline (PBS), fixed for 3 min at room 
temperature in 2% paraformaldehyde, washed, and incubated for 24 h at 37 °C with fresh SA-β-gal 
stain solution: 1 mg/mL 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal), 5 mM 
potassium ferrocyanide, 5 mM ferricyanide, 150 mM NaCl, 2 mM MgCl2, 0.01% sodium 
deoxycholate, and 0.02% Nonidet P-40. Senescence was expressed as the percentage of SA-β-gal-
positive cells over a total of 100 cells, manual count at 20× magnification by three independent 
investigators. The acidic β-galactosidase staining kit was from Invitrogen. 
Animals  
The animals received human care in compliance with the National Institutes of Health (NIH) Guide 
for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and in 
accordance with the Italian law (DL-116, January 27, 1992). The scientific project was supervised 
and approved by the local ethical committee. Pregnant female Sprague–Dawley rats (days 14 and 
15 of pregnancy) were purchased from Harlan Srl (Milan, Italy), caged allowing free access to 
water, and fed with a standard diet. Natural birth occurred 6–7 days later. 
Five experimental groups were studied, following a previously described protocol:(25) (1) control, 
rats received a single ip injection of citrate buffer (0.05 mM, pH 4.5) at day 1 of birth; (2) STZ, 
single ip injection of STZ (100 mg/kg body weight), dissolved in citrate buffer (day 1); (3) STZ + 
compound 1, single ip injection of STZ (day 1) followed by compound 1 (30 nmol/kg sc, twice 
daily), from day 2 to day 8; (4) STZ + compound 6, single ip injection of STZ (day 1) followed by 
compound 6 (30 nmol/kg sc, twice daily), from day 2 to day 8; (5) STZ + compound 6, single ip 
injection of STZ (day 1) followed by compound 6 (100 nmol/kg sc, twice daily), from day 2 to day 
8. Dams were randomly assigned to the five groups, and pups from the same litter were assigned to 
the same group. Pups were left with their mothers. All neonates were tested on day 2 for glycosuria 
with Glucofix (Menarini, Firenze, Italy). Only those animals that were glycosuric at day 2 after 
birth were included in the study. Number of animals in each group was as follows: 11 (control), 11 
(STZ), 16 (STZ + compound 1), 21 (STZ + compound 6, 30 nmol/kg), and 15 (STZ + compound 6, 
100 nmol/kg). Animals were killed at day 70 after birth by decapitation and blood samples 
immediately collected and centrifuged at 20000g for 2 min at 4 °C, then stored at −20 °C until 
assayed. 
Glucose and Insulin Analysis  
Plasma glucose levels were determined using a colorimetric assay (Glucofix, Menarini, Firenze, 
Italy) in nonfasted animals. Insulin was measured from pancreas (80 mg) and plasma by RIA, as 
previously described.(39) 
Statistical Analysis  
Statistical analyses were performed with Student’s t test for independent samples or by two-way 
ANOVA followed by Newman–Keuls post hoc test for multiple comparisons, using GraphPad 
Prism, version 5.0, software (GraphPad Software, Inc., San Diego, CA). Results are presented as the 
mean ± SE and considered significant for P < 0.05. 
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Abbreviations Used 
CD circular dichroism 
DCF-DA 5(and 6)-carboxy-2′,7′-dichlorofluorescein diacetate 
DCM dichloromethane 
DIC N,N′-diisopropylcarbodiimide 
DIEA N,N-diisopropylethylamine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
EDTA ethylenediaminetetraacetic acid 
EPC endothelial progenitor cell 
Ex-4 exendin-4 
FBS fetal bovine serum 
Fmoc fluorenylmethyloxycarbonyl 
GH growth hormone 
GRLN ghrelin receptor 
HATU 
2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluranium hexafluorophosphate 
methanaminium 
HFIP hexafluoroisopropanol 
HOBt hydroxybenzotriazole 
STZ streptozotocin 
IFN-γ interferon γ 
IL-1β interleukin-1β 
MBHA 4-methylbenzhydrylamine 
MPPA methylphenoxypropionic acid 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide 
NMM N-methylmorpholine 
PBS phosphate buffered saline 
PyBOP benzotriazol-1-yloxytrispyrrolidinophosphonium hexafluorophosphate 
RIA radioimmunoassay 
ROS reactive oxygen species 
RP-
HPLC 
reverse-phase high-performance liquid chromatography 
SA-β-gal senescence-associated β-galactosidase 
STZ streptozotocin 
TEA triethylamine 
TFA trifluoroacetic acid 
TNF-α tumor necrosis factor α 
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